{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:20:06Z","timestamp":1790439606670,"version":"4.1.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To identify and assess the current literature surrounding the safety, efficacy, and practical considerations of brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed or refractory (r\/r) mantle cell lymphoma (MCL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>An English-based literature search was conducted using the terms \u201c brexucabtagene autoleucel\u201d AND \u201c mantle cell lymphoma\u201d OR \u201c KTE-X19\u201din PubMed (inception through May 1, 2021), EMBASE (inception through May 1, 2021), and ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All studies evaluating the use of brexu-cel in MCL were considered for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In the pivotal ZUMA-2 trial, brexu-cel demonstrated objective response and complete response rates of 85% and 59%, respectively. These results were consistent among high-risk subgroups. Noteworthy treatment-related adverse effects included grade \u22653 cytopenias (94%), immune effector cell\u2013associated neurotoxicity syndrome (31%), and cytokine release syndrome (15%). Brexu-cel elicited a toxicity profile similar to that of other novel chimeric antigen receptor (CAR) T-cell products, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>There are currently no head-to-head clinical trials evaluating brexu-cel against other approved subsequent-line options in r\/r MCL. In a relatively small phase II trial, brexu-cel demonstrated impressive response rates in heavily pretreated patients, with few viable alternatives. Long-term safety and efficacy outcomes with brexu-cel are unknown. The prevention, identification, and management of unique CAR T-cell toxicities requires expert care from a well-trained interdisciplinary team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Brexu-cel has emerged as a viable treatment option in MCL. Additional studies are required to determine the optimal sequencing and place in therapy for brexu-cel in this highly heterogeneous, pathobiologically distinct, and incurable malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211026338","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:39:32Z","timestamp":1627951172000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma"],"prefix":"10.1177","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-3356","authenticated-orcid":false,"given":"Mary Kate","family":"Anderson","sequence":"first","affiliation":[{"name":"The Children\u2019s Hospital at Saint Francis, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-978X","authenticated-orcid":false,"given":"Annie","family":"Torosyan","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"bibr1-10600280211026338","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"bibr2-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"bibr3-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487"},{"key":"bibr4-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392"},{"key":"bibr5-10600280211026338","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (version 2.2021). Accessed March 10, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"bibr6-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"bibr7-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.291"},{"key":"bibr8-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8071"},{"key":"bibr9-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"bibr10-10600280211026338","unstructured":"Yescarta\u00ae. Package insert. Kite Pharma Inc; 2020."},{"key":"bibr11-10600280211026338","unstructured":"Kymriah\u00ae. Package insert. Novartis Pharmaceuticals Corporation; 2018."},{"key":"bibr12-10600280211026338","unstructured":"Tecartus\u2122. Package insert. Kite Pharma Inc; 2020."},{"key":"bibr13-10600280211026338","unstructured":"Breyanzi\u00ae. Package insert. Juno Therapeutics Inc; 2021."},{"key":"bibr14-10600280211026338","unstructured":"Abecma\u2122. Package insert. Celgene Corporation; 2021."},{"key":"bibr15-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1568-1"},{"key":"bibr16-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.12.004"},{"key":"bibr17-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1889510"},{"key":"bibr18-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr19-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"bibr20-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"bibr21-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017506"},{"key":"bibr22-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"key":"bibr23-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7006"},{"key":"bibr24-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr25-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511"},{"key":"bibr26-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr27-10600280211026338","unstructured":"Actemra\u00ae. Package insert. Genentech; 2017."},{"key":"bibr28-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"bibr29-10600280211026338","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00888"},{"key":"bibr30-10600280211026338","volume-title":"Common Terminology Criteria for Adverse Events Version 4.03","author":"US Department of Health and Human Services","year":"2010"},{"key":"bibr31-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"bibr32-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr33-10600280211026338","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"bibr34-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"bibr35-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-"},{"key":"bibr36-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"bibr37-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"bibr38-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"bibr39-10600280211026338","unstructured":"IBM Corporation. IBM Micromedex\u00ae. Accessed March 2, 2021. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/51E01A\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/404BFD\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.FindRedBook?navitem=topRedBook&isToolPage=true"},{"key":"bibr40-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01691"},{"key":"bibr41-10600280211026338","unstructured":"Avalere. CMS finalizes new reimbursement method for CAR-T treatments. Accessed March 9, 2021. https:\/\/avalere.com\/insights\/cms-proposes-significant-changes-to-reimbursement-mechanisms-for-car-t"},{"key":"bibr42-10600280211026338","unstructured":"Kite Konnect. Patient assistance programs. Accessed March 9, 2021. https:\/\/www.kitekonnectrefer.com\/s\/patient-assistance-programs"},{"key":"bibr43-10600280211026338","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1894158"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211026338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211026338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211026338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:19Z","timestamp":1777374979000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211026338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1177\/10600280211026338"],"URL":"https:\/\/doi.org\/10.1177\/10600280211026338","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}